ResearcherHarvard UniversityActive in the last 2 years
Marcela Valderrama Maus
Matched on ORCID iD 0000-0002-7578-0393; OpenAlex author ID A5029763484; NIH RePORTER profile ID 10066497. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 2)
- Trials
- 0
- Grants
- 3
- Labs led
- 1
- Collaborators
- 16
2023: 1 paper · 2024: 1 paper, 1 grant · 2025: 1 paper · 2026: 2 papers, 2 grants
Papers 5
- Optimizing CAR T cell therapy in pancreatic cancer through clinically actionable combinations. First author DOI 10.1016/j.omton.2026.201231↗
- Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-25-2907↗
- Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer. Last author DOI 10.1038/s41467-025-66102-2↗
- Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma. Last author DOI 10.1158/1078-0432.ccr-23-3841↗
- Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-2245↗
Grants 3
- Novel CAR T cell engineering strategies for effective eradication of solid and liquid tumors R01CA238268↗
- CAR T cells targeting mesothelin and secreting bispecific antibodies targeting fibroblasts in pancreatic cancer UH3CA283619↗
- CAR T cells targeting mesothelin and secreting bispecific antibodies targeting fibroblasts in pancreatic cancer UG3CA283619↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Giulia Escobar · 3 shared papers, 2025–2026 · strength 1.10
- Paper Optimizing CAR T cell therapy in pancreatic cancer through clinically actionable combinations. DOI 10.1016/j.omton.2026.201231↗
- Paper Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Canc… DOI 10.1158/1078-0432.ccr-25-2907↗
- Paper Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer. DOI 10.1038/s41467-025-66102-2↗
- Diego Salas‐Benito · 3 shared papers, 2024–2026 · strength 0.61
- Paper Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Canc… DOI 10.1158/1078-0432.ccr-25-2907↗
- Paper Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer. DOI 10.1038/s41467-025-66102-2↗
- Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
- Sangwoo Park · 2 shared papers, 2025–2026 · strength 0.47
- Alexander Armstrong · 1 shared paper, 2026 · strength 0.25
- Eli P. Darnell · 1 shared paper, 2025 · strength 0.22
- Kimberly R. Hagel · 1 shared paper, 2023 · strength 0.18
- William C. Hahn · 1 shared paper, 2023 · strength 0.18
- David Tsai Ting · 1 shared paper, 2024 · strength 0.14
- Marc Wehrli · 1 shared paper, 2024 · strength 0.14
- Samantha R. Guinn · 1 shared paper, 2024 · strength 0.14
- Genevieve Marie Boland · 1 shared paper, 2024 · strength 0.14
- Richard Andrew Burkhart · 1 shared paper, 2024 · strength 0.14
- Elizabeth M. Jaffee · 1 shared paper, 2024 · strength 0.14
- Andrew Scott Liss · 1 shared paper, 2024 · strength 0.14
- Lei Zheng · 1 shared paper, 2024 · strength 0.14
- Jacquelyn W. Zimmerman · 1 shared paper, 2024 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.